News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Captured microbes are then neutralized on engineered microbicidal surfaces
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Subscribe To Our Newsletter & Stay Updated
